Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 163
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A075F648F69EN
Leaflet:

Download PDF Leaflet

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis – Pipeline Review, H2 2016, provides an overview of the Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline landscape.

Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 7, 2, 7, 2, 13, 6 and 2 respectively.Ankylosing Spondylitis.

Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ankylosing Spondylitis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Musculoskeletal Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ankylosing Spondylitis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Ankylosing Spondylitis (Bekhterev's Disease) Overview
Therapeutics Development
Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Overview
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics under Development by Companies
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Ankylosing Spondylitis (Bekhterev's Disease) - Products under Development by Companies
Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development
AbbVie Inc
Alteogen Inc.
Amgen Inc.

BIOCAD

Biocon Limited
Bionovis SA
Brickell Biotech, Inc.
Celgene Corporation
Coherus BioSciences, Inc.
Genor BioPharma Co Ltd
Innovent Biologics, Inc.
Johnson & Johnson
Momenta Pharmaceuticals, Inc.
Mycenax Biotech Inc.
NeuClone Pty Ltd
Novartis AG
Oncobiologics, Inc.
Panacea Biotec Limited
Protalix BioTherapeutics, Inc.
Reliance Life Sciences Pvt. Ltd.
Sandoz International GmbH
Shanghai Pharmaceutical Co., Ltd.
Therapeutic Proteins International, LLC
Vitae Pharmaceuticals, Inc.
Xbrane Biopharma AB
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
apremilast - Drug Profile
BBI-6000 - Drug Profile
certolizumab pegol biosimilar - Drug Profile
DNX-114 - Drug Profile
DNX-514 - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
golimumab - Drug Profile
golimumab biosimilar - Drug Profile
golimumab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
INV-17 - Drug Profile
risankizumab - Drug Profile
secukinumab - Drug Profile
thalidomide - Drug Profile
upadacitinib tartrate - Drug Profile
VTP-43742 - Drug Profile
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products
Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 160

LIST OF TABLES

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AbbVie Inc, H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Alteogen Inc., H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Amgen Inc., H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by BIOCAD, H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Limited, H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Bionovis SA, H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Brickell Biotech, Inc., H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celgene Corporation, H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Coherus BioSciences, Inc., H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Genor BioPharma Co Ltd, H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Innovent Biologics, Inc., H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Johnson & Johnson, H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mycenax Biotech Inc., H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by NeuClone Pty Ltd, H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Novartis AG, H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Oncobiologics, Inc., H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Panacea Biotec Limited, H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz International GmbH, H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Pharmaceutical Co., Ltd., H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Therapeutic Proteins International, LLC, H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Xbrane Biopharma AB, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects (Contd..1), H2 2016
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H2 2016 148

LIST OF FIGURES

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: